Taysha Gene Therapies, Inc. Long-Term Debt, Maturity, Year Two
Taysha Gene Therapies, Inc. (TSHA) had Long-Term Debt, Maturity, Year Two of $20.00 million as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2023-11-14
- 2023-09-30: Long-Term Debt, Maturity, Year Two $20.00M.
- 2023-06-30: Long-Term Debt, Maturity, Year Two $20.00M.
- 2023-03-31: Long-Term Debt, Maturity, Year Two $20.00M.
- 2022-09-30: Long-Term Debt, Maturity, Year Two $6.67M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2023-09-30 | $20.00M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $20.00M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $20.00M 10-Q · filed 2023-05-11 |
| 2022-09-30 | $6.67M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $6.67M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $6.67M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |